Overview

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Status:
Terminated

Trial end date:
2004-10-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to compare the efficacy and safety of lanreotide Autogel and Sandostatin LAR Depot, to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with carcinoid syndrome.

Phase:

Phase 3

Details

Lead Sponsor:

Ipsen

Treatments:

Angiopeptin
Lanreotide
Octreotide
Somatostatin